Track market-moving stories before they get noisy

Align Technology, Inc. (NASDAQ:ALGN – Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 2,293 call options on the stock. This represents an increase of 72% compared to the typical daily volume of 1,334 call options.

Analysts Set New Price Targets A number of analysts recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Align Technology in a report on Thursday, July 30th. UBS Group reiterated a “neutral” rating and set a $189.00 target price on shares of Align Technology in a research note on Thursday, July 23rd. BMO Capital Markets started coverage on shares of Align Technology in a report on Wednesday, July 8th. They issued an “outperform” rating and a $209.00 price target on the stock. Weiss Ratings upgraded shares of Align Technology from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday. Finally, Zacks Research lowered shares of Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $206.36.

Check Out Our Latest Stock Report on Align Technology

Shares of NASDAQ ALGN opened at $153.49 on Wednesday. The stock has a fifty day simple moving average of $170.91 and a two-hundred day simple moving average of $173.44. Align Technology has a 1-year low of $122.00 and a 1-year high of $200.43. The firm has a market cap of $10.99 billion, a price-to-earnings ratio of 26.69, a price-to-earnings-growth ratio of 1.69 and a beta of 1.65. Align Technology (NASDAQ:ALGN – Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.02. Align Technology had a return on equity of 15.86% and a net margin of 9.99%.The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period last year, the business posted $2.49 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. Analysts forecast that Align Technology will post 9.38 EPS for the current year.

Institutional Investors Weigh In On Align Technology Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its holdings in Align Technology by 5.9% during the second quarter. NewEdge Advisors LLC now owns 2,826 shares of the medical equipment provider’s stock valued at $477,000 after purchasing an additional 157 shares during the last quarter. Squarepoint Ops LLC boosted its position in Align Technology by 101.1% during the second quarter. Squarepoint Ops LLC now owns 3,567 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 1,793 shares during the period. Baird Financial Group Inc. increased its stake in shares of Align Technology by 11.2% in the second quarter. Baird Financial Group Inc. now owns 128,428 shares of the medical equipment provider’s stock worth $21,661,000 after purchasing an additional 12,945 shares in the last quarter. Beacon Investment Advisory Services Inc. increased its stake in shares of Align Technology by 14.7% in the second quarter. Beacon Investment Advisory Services Inc. now owns 3,081 shares of the medical equipment provider’s stock worth $520,000 after purchasing an additional 394 shares in the last quarter. Finally, Allworth Financial LP raised its position in shares of Align Technology by 3.1% in the second quarter. Allworth Financial LP now owns 3,393 shares of the medical equipment provider’s stock valued at $572,000 after purchasing an additional 101 shares during the period. 88.43% of the stock is currently owned by institutional investors.

About Align Technology (Get Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Further Reading Five stocks we like better than Align Technology Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Canada Pension Plan Investment Board bought a new position in Align Technology, Inc. (NASDAQ:ALGN – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 26,510 shares of the medical equipment provider’s stock, valued at approximately $4,471,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Osterweis Capital Management Inc. purchased a new position in shares of Align Technology during the second quarter worth approximately $36,000. Parkman Healthcare Partners LLC bought a new position in shares of Align Technology during the 2nd quarter valued at $6,234,000. Legal & General Group Plc bought a new position in shares of Align Technology during the 2nd quarter valued at $22,542,000. The Manufacturers Life Insurance Company purchased a new position in Align Technology in the 2nd quarter worth $13,007,000. Finally, Vega Investment Solutions purchased a new position in Align Technology in the 2nd quarter worth $476,000. 88.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth Several analysts have issued reports on ALGN shares. Needham & Company LLC restated a “hold” rating on shares of Align Technology in a research report on Thursday, July 30th. BMO Capital Markets started coverage on Align Technology in a report on Wednesday, July 8th. They issued an “outperform” rating and a $209.00 price objective on the stock. Weiss Ratings lowered Align Technology from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. UBS Group reissued a “neutral” rating and issued a $189.00 target price on shares of Align Technology in a research note on Thursday, July 23rd. Finally, Zacks Research cut Align Technology from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Align Technology currently has a consensus rating of “Moderate Buy” and a consensus price target of $206.36.

View Our Latest Research Report on Align Technology Align Technology Price Performance NASDAQ:ALGN opened at $157.58 on Monday. The firm has a market capitalization of $11.29 billion, a P/E ratio of 27.41, a P/E/G ratio of 1.67 and a beta of 1.65. The company has a fifty day moving average of $173.01 and a 200 day moving average of $175.03. Align Technology, Inc. has a 52 week low of $122.00 and a 52 week high of $200.43.

Align Technology (NASDAQ:ALGN – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.02. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion. Align Technology had a net margin of 9.99% and a return on equity of 15.86%. The company’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.49 EPS. As a group, analysts anticipate that Align Technology, Inc. will post 9.38 EPS for the current year.

Align Technology Company Profile (Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Further Reading Five stocks we like better than Align Technology Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

On August 17, 2026, Align Technology Inc
ALGN -5.6% 89

shares fell 5.6%, bringing the current price to $171.16. The stock has experienced a 52-week range of $122.00 to $200.44, reflecting volatility in the market.

GF Value™ verdict: Align Technology Inc is currently priced at $171.16, which is 23.6% below the GF Value™ estimate of $224.16, indicating it is undervalued.GF Score™ of 89/100 signals a strong company with solid overall fundamentals.Insider activity reveals that insiders sold $1.5M worth of shares over the past 12 months with no buying, suggesting cautious sentiment among insiders.Is ALGN Overvalued or Undervalued?According to GuruFocus, the GF Value™ estimate for Align Technology Inc is $224.16, which means the current price of $171.16 is significantly below this intrinsic value. This 23.6% margin of safety suggests an opportunity for investors looking for undervalued stocks. The GF Valuation label indicates that the stock is modestly undervalued, based on a comprehensive analysis of historical trading multiples, business performance, and future growth estimates.

While the undervaluation presents a potential opportunity, it is essential to consider market conditions and company performance that may affect future valuations. The stock's recent decline could be a response to broader market trends or specific company news that has yet to be fully assessed by the market.

How Does ALGN's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)29.8x38.5xForward P/E15.1xN/AAlign Technology's current P/E (TTM) of 29.8x is significantly lower than its 5-year median P/E of 38.5x, indicating that the stock is trading at a discount compared to its historical valuation. This aligns with the GF Value™ verdict, reinforcing the notion that ALGN is undervalued in the current market conditions.

What Does ALGN's GF Score™ Tell Us?The GF Score™ is a composite rating that evaluates a company's financial strength, profitability, growth, valuation, and momentum, helping investors understand the overall quality of the investment. Align Technology's GF Score™ of 89/100 reflects strong fundamentals, with its most notable strengths in profitability (9/10) and valuation (8/10), while its growth rank (7/10) and financial strength (7/10) are solid but comparatively weaker.

MetricRatingGF Score™89Financial Strength7/10Profitability9/10Growth7/10Valuation8/10Momentum8/10The strong GF Score™ indicates that Align Technology is performing well across multiple metrics, particularly in profitability, which could attract potential investors. However, the company should focus on improving its financial strength and growth ranks to enhance its overall appeal further.

What Are Gurus and Insiders Doing with ALGN?Currently, six gurus hold shares of Align Technology Inc, with four increasing their positions and three trimming theirs in recent quarters. This mixed activity suggests a level of confidence among some institutional investors while also reflecting caution among others. The presence of multiple gurus indicates a level of interest and support for the stock, which can be a positive signal for potential investors.

On the insider front, the sale of $1.5M in shares over the past 12 months, without any buying activity, may raise concerns regarding the outlook from those closest to the company. This selling pattern could suggest that insiders are not optimistic about the near-term performance of the stock, which is an important consideration for any investment decision.

What This Means for InvestorsBased on the GF Value™ analysis, Align Technology Inc appears to be undervalued at its current price of $171.16, with a substantial margin of safety identified. However, the insider selling activity and mixed signals from guru ownership introduce a level of caution. It is essential for investors to weigh these factors carefully while considering Align Technology's potential. For further information, readers can visit the Align Technology Inc
ALGN -5.6% 89

stock page and explore the GF Value™ page for a deeper analysis.

Frequently Asked QuestionsWhat is ALGN's GF Score™?

Align Technology Inc has a GF Score™ of 89/100, indicating strong overall fundamentals and a solid position within its industry.

Is ALGN overvalued or undervalued?

According to the GF Value™ estimate, ALGN is currently undervalued, with a price that is 23.6% below its intrinsic value of $224.16.

What is ALGN's P/E ratio?

Align Technology's P/E (TTM) ratio is 29.8x, which is significantly below its 5-year median P/E of 38.5x, suggesting that the stock is undervalued compared to its historical performance.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Key Takeaways Align recorded a $37.5M U.K. VAT liability after the tribunal reversed the prior tax exemption.Align will charge 20% VAT on certain U.K. products from Sept. 7 while keeping list prices unchanged. ALGN expects about 6% Clear Aligner volume growth as international demand helps offset U.K. uncertainty. Align Technology (ALGN - Free Report) is dealing with a new U.K. tax issue in 2026. A July Upper Tribunal decision overturned the prior value-added tax exemption for clear aligners, adding a fresh earnings and pricing variable.

The ruling arrives as international Clear Aligner demand remains healthy but foreign exchange, softer retail demand and scanner mix continue to complicate the margin picture.

ALGN Absorbs a $37.5 Million U.K. VAT LiabilityAlign recorded an estimated $37.5 million liability, including interest, after the U.K. Upper Tribunal reversed the earlier VAT-exemption ruling. The charge makes the dispute an immediate earnings matter rather than a legal issue with only future consequences.

The accrual also contributed to higher second-quarter operating expenses. Those expenses rose 10.7% year over year to $603.4 million, with the U.K. VAT accrual and higher employee compensation among the main drivers.

In the past year, ALHC shares have risen 25.1% compared with the industry’s 21.5% growth. 

Image Source: Zacks Investment Research

Align Will Add 20% VAT Without Raising List PricesFrom Sept. 7, 2026, Align plans to charge 20% VAT on applicable U.K. Invisalign aligners and Vivera retainers while keeping list prices unchanged. That changes the economics of an established product line without changing published list prices.

The development adds another pricing variable in the U.K. Align already expects 2026 Clear Aligner average selling prices to be flat to slightly down from 2025, reflecting broader mix pressure across countries and products.

Per the Zacks Consensus Estimate, the company’s 2026 revenues are pegged at $4.17 billion, indicating 3.3% year over year growth. 

Image Source: Zacks Investment Research

ALGN’s Appeal Keeps the Final Cost UncertainAlign plans to appeal the tribunal decision, so the final financial outcome remains unresolved. The $37.5 million liability is already recorded, but the longer-term cost and operating consequences will depend on how the appeal process develops.

That distinction matters for investors. The current accrual is visible in 2026 results, while the durability of the VAT treatment remains uncertain and could continue to influence how Align manages the U.K. business.

Align Faces the VAT Issue Amid Other Margin PressuresForeign exchange was already weighing on profitability before the VAT issue became more prominent. In the second quarter, currency movements reduced gross margin by about 0.8 percentage points and operating margin by about 1.4 points year over year.

The broader dental market provides useful context. DENTSPLY SIRONA Inc. (XRAY - Free Report) manufactures professional dental products and technologies across equipment, consumables and specialty products. Henry Schein, Inc. (HSIC - Free Report) supplies office-based dental practitioners with merchandise, equipment and technology solutions, making both relevant industry reference points even though Align’s VAT dispute is company-specific.

ALGN’s Global Growth Helps Offset the U.K. RiskInternational Clear Aligner growth remains a counterweight. Second-quarter volume increased at double-digit rates in both EMEA and APAC, while Latin America delivered record second-quarter shipments.

That geographic momentum supports Align’s broader 2026 volume outlook. Management now expects Clear Aligner volume growth of approximately 6%, leaving investors to weigh expanding international demand against the incremental cost and uncertainty concentrated in the U.K.

Align’s Ratings Point to Caution Around the EventThe VAT ruling has already created a measurable charge, while the appeal leaves the longer-term impact unsettled. For 2026, the issue adds to currency and mix pressures rather than standing alone as the only driver of Align’s earnings outlook.

ALGN currently carries a Zacks Rank #3 (Hold), with a Value Score of B, Growth Score of B, VGM Score of B and Momentum Score of F. The B scores are favorable within the Style Score framework, but the F Momentum Score signals weak timing support. That combination is consistent with monitoring the appeal and operating impact rather than treating the VAT ruling by itself as a decisive bullish or bearish catalyst.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign System of clear

Posted by Defense World Staff on Aug 10th, 2026

Contravisory Investment Management Inc. acquired a new stake in Align Technology, Inc. (NASDAQ:ALGN – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,557 shares of the medical equipment provider’s stock, valued at approximately $1,106,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ALGN. Blue Trust Inc. boosted its holdings in Align Technology by 77.5% in the first quarter. Blue Trust Inc. now owns 158 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 69 shares in the last quarter. Sunbelt Securities Inc. raised its holdings in Align Technology by 222.4% during the fourth quarter. Sunbelt Securities Inc. now owns 158 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 109 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new stake in shares of Align Technology during the 2nd quarter worth approximately $36,000. Tobam acquired a new position in shares of Align Technology in the 4th quarter valued at $30,000. Finally, Hollencrest Capital Management acquired a new position in shares of Align Technology in the 1st quarter valued at $34,000. Institutional investors and hedge funds own 88.43% of the company’s stock.

Align Technology Price Performance ALGN stock opened at $173.66 on Monday. The company has a market cap of $12.44 billion, a price-to-earnings ratio of 30.20, a price-to-earnings-growth ratio of 1.85 and a beta of 1.65. The company has a fifty day moving average price of $175.06 and a 200 day moving average price of $175.30. Align Technology, Inc. has a 12 month low of $122.00 and a 12 month high of $200.43.

Align Technology (NASDAQ:ALGN – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.02. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. Align Technology had a net margin of 9.99% and a return on equity of 15.86%. Align Technology’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period last year, the firm posted $2.49 EPS. As a group, analysts anticipate that Align Technology, Inc. will post 9.38 earnings per share for the current year.

Align Technology declared that its Board of Directors has initiated a stock buyback plan on Wednesday, April 29th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 1.6% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth Several equities research analysts recently commented on ALGN shares. Needham & Company LLC reiterated a “hold” rating on shares of Align Technology in a research note on Thursday, July 30th. Wall Street Zen downgraded shares of Align Technology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Citigroup started coverage on Align Technology in a report on Wednesday, April 15th. They issued a “buy” rating and a $240.00 target price for the company. Morgan Stanley upped their target price on Align Technology from $169.00 to $188.00 and gave the company an “equal weight” rating in a research report on Friday, April 24th. Finally, Evercore upped their target price on Align Technology from $200.00 to $220.00 in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $206.36.

Read Our Latest Report on Align Technology

About Align Technology (Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Featured Articles Five stocks we like better than Align Technology Albemarle’s Blowout Quarter Shows Why Lithium Still Matters Can DICK’S Turn Foot Locker Into a Winner? Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War Want to see what other hedge funds are holding ALGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Align Technology, Inc. (NASDAQ:ALGN – Free Report).

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia State Teachers Retirement System Boosts Position in Steven Madden, Ltd. $SHOO

NEXT HEADLINE »Echostar CORP $ECHO Shares Purchased by Contravisory Investment Management Inc.

Align Technology delivers record revenue, volume, and operating margins, yet trades near five-year valuation lows despite structural business improvements. Competitive pressures have eased post-SmileDirectClub exit, with ALGN retaining dominant market share and shifting growth toward international and DSO channels. Operating margins are expanding, management continues to raise guidance, and a robust buyback program is underway, supported by strong free cash flow.

Posted by Defense World Staff on Aug 3rd, 2026

California State Teachers Retirement System grew its position in shares of Align Technology, Inc. (NASDAQ:ALGN – Free Report) by 21.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 79,293 shares of the medical equipment provider’s stock after buying an additional 13,867 shares during the period. California State Teachers Retirement System owned approximately 0.11% of Align Technology worth $13,593,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ALGN. Capital International Investors grew its stake in shares of Align Technology by 52.2% in the fourth quarter. Capital International Investors now owns 4,643,221 shares of the medical equipment provider’s stock valued at $725,039,000 after acquiring an additional 1,592,848 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. bought a new position in Align Technology during the fourth quarter worth about $190,899,000. Norges Bank acquired a new stake in Align Technology in the 4th quarter worth about $155,556,000. Assenagon Asset Management S.A. raised its stake in Align Technology by 413.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 989,388 shares of the medical equipment provider’s stock worth $169,611,000 after purchasing an additional 796,529 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Align Technology by 247.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,005,413 shares of the medical equipment provider’s stock valued at $156,995,000 after purchasing an additional 715,919 shares during the period. Institutional investors and hedge funds own 88.43% of the company’s stock.

Trending Headlines about Align Technology Here are the key news stories impacting Align Technology this week:

Positive Sentiment: Q2 results exceeded expectations. Align reported adjusted earnings of $2.64 per share and revenue of approximately $1.06 billion, topping consensus estimates. Revenue increased 4.3% year over year, while record Clear Aligner shipments and improved non-GAAP margins supported profitability. Align Technology Q2 Earnings and Revenues Top Estimates Positive Sentiment: Digital orthodontics remains a growth focus. Management highlighted expanding digital workflows, connected orthodontic tools and long-term opportunities for Invisalign, iTero scanners and exocad software. The company’s 2026 outlook was reaffirmed, while an orthodontic summit showcased its product and technology strategy. ALGN Q2 Earnings Call Highlights Digital Growth Push Positive Sentiment: Board changes could improve shareholder value. Following discussions with Elliott Investment Management, Align plans to add three independent directors and conduct an operational review. The initiatives may increase accountability, improve execution and identify opportunities to enhance returns. Align Technology to Overhaul Board Following Engagement with Elliott Neutral Sentiment: Valuation is viewed as more attractive after the pullback. Some analysts see ALGN as reasonably valued, but believe the stock needs faster growth to generate sustained upside. Align Technology: Attractively Valued, But Growth Still Needs To Pick Up Negative Sentiment: Near-term guidance and execution remain concerns. Third-quarter revenue guidance of roughly $1.0 billion was described as slightly below or around expectations, limiting the benefit of the earnings beat. Negative Sentiment: Systems weakness is capping upside. Analysts noted softer scanner and systems performance, along with pricing pressure, despite strong Clear Aligner volumes. Needham maintained a Hold rating. Align Technology Hold Rating Maintained Negative Sentiment: Growth is still relatively modest. Investors may remain cautious because revenue growth has not yet accelerated enough to justify a more bullish outlook, even with improving margins and record aligner shipments. Align Technology Price Performance ALGN stock opened at $169.16 on Monday. Align Technology, Inc. has a 12 month low of $122.00 and a 12 month high of $200.43. The firm has a market cap of $12.12 billion, a P/E ratio of 29.42, a P/E/G ratio of 1.78 and a beta of 1.65. The company’s 50-day moving average price is $174.55 and its two-hundred day moving average price is $175.23.

Align Technology (NASDAQ:ALGN – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 EPS for the quarter, beating the consensus estimate of $2.62 by $0.02. Align Technology had a net margin of 9.99% and a return on equity of 15.86%. The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the previous year, the company earned $2.49 EPS. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. Equities analysts predict that Align Technology, Inc. will post 9.48 EPS for the current year.

Align Technology announced that its board has authorized a stock repurchase program on Wednesday, April 29th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the medical equipment provider to repurchase up to 1.6% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets ALGN has been the topic of a number of analyst reports. UBS Group restated a “neutral” rating and set a $189.00 target price on shares of Align Technology in a research report on Thursday, July 23rd. BMO Capital Markets initiated coverage on shares of Align Technology in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $209.00 price target for the company. Evercore boosted their price target on Align Technology from $200.00 to $220.00 in a research note on Thursday, April 30th. Morgan Stanley increased their price target on Align Technology from $169.00 to $188.00 and gave the stock an “equal weight” rating in a research report on Friday, April 24th. Finally, Wall Street Zen lowered Align Technology from a “strong-buy” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $206.36.

Check Out Our Latest Stock Analysis on Align Technology

About Align Technology (Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Read More Five stocks we like better than Align Technology 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story AbbVie Quietly Solved Its Biggest Problem—Now What? Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade Strategy’s Structural Strength: Hidden in a $8 Billion Illusion

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEFinancial Solutions Advisory Group Inc. Makes New Investment in Caterpillar Inc. $CAT

Align Technology delivered record Q2 revenue and clear aligner volumes, with robust international growth offsetting North American stagnation. ALGN's strategy centers on expanding its digital dentistry platform, leveraging financing, lower-cost products, and ecosystem growth to drive recurring revenue. Valuation at $173 per share (15–16x forward earnings) is attractive for a market leader with high margins, net cash, and ongoing share buybacks.

Key Takeaways Align Technology reported record 691,785 clear aligner shipments, up 7.4% year over year.ALGN expanded scanner adoption as flexible models grew the digital platform and installed base.Align focused on margin gains, buybacks and strategic reviews while maintaining 2026 outlook. Align Technology, Inc. (ALGN - Free Report) used its second-quarter 2026 earnings call to emphasize continued Invisalign momentum, expanding digital workflows and efforts to improve operating leverage. Management highlighted record clear aligner volumes while acknowledging near-term pressure from scanner pricing changes and flexible purchasing models.

The discussion centered on balancing current revenue mix challenges with longer-term platform expansion. Executives also addressed strategic reviews, capital allocation and investor questions around North America demand trends.

ALGN Advances Clear Aligner MomentumCEO Joseph Hogan said growth remained broad-based across geographies, customer channels and patient segments. Clear Aligner shipments reached a record 691,785 cases in the quarter, up 7.4% year over year, supported by international expansion and stable North American performance.

Hogan noted that adoption continued among orthodontists, general practitioners and dental support organizations. He highlighted investments in patient financing, clinical support programs and doctor subscription offerings as tools supporting utilization and patient conversion.

The company also pointed to continued strength among younger patients. Teen and growing patient treatment starts increased 7.2% year over year to 240,000 Invisalign cases, supported by adoption of newer treatment solutions.

Align Expands Digital Platform StrategyAlign Technology’s scanner strategy remained a major discussion point during the call. Management said Systems and Services revenues declined 10.8% year over year to $185.3 million due to lower scanner average selling prices and greater use of leasing and rental models.

CFO John Morici explained that the shift toward flexible acquisition options is intentional. The company is accepting lower upfront revenues to increase scanner adoption and expand future treatment opportunities through its digital platform.

Management highlighted that scanner placements to new doctors reached a record level, while the active scanner installed base grew approximately 11% year over year. The company said these trends support broader digital workflow adoption.

ALGN Focuses on Margins and CashThe company reported second-quarter revenues of $1.06 billion, up 4.3% year over year, beating the consensus mark of $1.05 billion. Non-GAAP adjusted EPS increased to $2.64 from $2.49 a year earlier, surpassing the Zacks Consensus Estimate of $2.56.

Morici said margin improvements were supported by operational efficiencies, higher Clear Aligner average selling prices and manufacturing improvements. Non-GAAP operating margin reached 22.9%, up from 21.3% in the prior-year period.

ALGN ended the quarter with $1.1 billion in cash and repurchased approximately 393,400 shares for about $67 million. Management increased its 2026 repurchase expectation to $400 million to $500 million.

Align Adjusts Outlook for 2026Management maintained its expectation for 2026 revenue growth of 3% to 4% year over year. Clear Aligner volume growth is expected to be approximately 6%, while Systems and Services revenues are projected to decline 6% to 8%.

For the third quarter, Align expects revenues of $1.0 billion to $1.02 billion. Management expects continued scanner mix pressure and seasonal factors to affect Systems and Services results.

The company also expects restructuring and other one-time charges to affect third-quarter margins. Full-year non-GAAP operating margin is expected to improve by about 100 basis points from the 2025 levels.

ALGN Addresses Investor QuestionsA Leerink Partners analyst asked about confidence in maintaining Invisalign case growth despite consumer uncertainty. Hogan pointed to the company’s global mix, including strength in APAC, Europe and Latin America, as a factor supporting resilience.

A Stifel analyst questioned whether North American independent practices were improving and whether financing initiatives could help demand. Hogan said the company remains focused on product innovation, affordability programs and expanded treatment options.

Analysts also pressed management on scanner revenue pressure. Executives reiterated that lower upfront scanner economics are part of a broader strategy to expand the installed base and create future treatment revenue opportunities.

Align Maintains Long-Term Growth FocusManagement emphasized that strategic priorities remain centered on digital orthodontics, restorative dentistry and expanding patient access. Hogan said the company is continuing efforts to improve execution, strengthen innovation and increase operating leverage.

Align also announced plans to add independent directors and conduct a strategic and operating model review following discussions with Elliott Management. The company said the review is intended to improve commercial execution and organizational effectiveness.

The company’s next phase will depend on balancing near-term scanner revenue pressure with long-term digital platform expansion. Management continues to focus on adoption, utilization and margin improvement.

ALGN’s Zacks Rank and Style Score SignalsALGN carries a Zacks Rank #4 (Sell), indicating that earnings estimate revision trends currently point to weaker potential performance relative to higher-ranked stocks. The Zacks Rank can change as analysts update earnings expectations following new financial results.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The stock has a Value Score of C, Growth Score of A, Momentum Score of D and VGM Score of B. Zacks Style Scores are designed to complement the Zacks Rank by evaluating characteristics such as value, growth and momentum, with stronger scores generally indicating more favorable traits.

Align Technology, Inc. (ALGN) Q2 2026 Earnings Call Transcript

Why These 3 Tech Stocks Could Be the Best Opportunities You're OverlookingAlign Technology NASDAQ: ALGN reported record second-quarter revenue of $1.06 billion, up 4.3% from a year earlier, as record clear aligner volumes and higher revenue in that business offset continued weakness in its systems and services segment.

Chief Executive Officer Joe Hogan said second-quarter results were supported by clear aligner shipments of 692,000 cases, a 7.4% year-over-year increase. Clear aligner revenue rose 8.2% to $870.9 million, while the company’s average per-case shipment price increased 0.8% to $1,260.

Get Align Technology alerts:

Buy the Dip? These Earnings Misses Offer Long-Term Upside“Q2 2026 revenues and clear aligner volumes were in line with our outlook, while clear aligner ASPs and non-GAAP operating margin of 22.9% exceeded our expectations,” Hogan said.

Clear aligner growth led by international markets Align said clear aligner volume growth was driven by double-digit expansion in Asia-Pacific, Europe, the Middle East and Africa, and Latin America, while North American performance was relatively stable. The company cited continued adoption among orthodontists, general-practice dentists and dental service organizations, or DSOs.

MarketBeat Week in Review: 12/25 - 12/29Record 89,200 doctors submitted Invisalign cases in the quarter, a 3.4% increase from a year earlier, while doctor utilization rose 3.8%. Shipments to orthodontists increased 7.8%, and shipments to general-practice dentists rose 6.6%.

Teen and growing-patient treatment starts increased 7.2% to 240,000 Invisalign cases, with growth led by China, Japan, Turkey, India and Brazil. Hogan said adoption of Invisalign First, the Invisalign Palatal Expander and Invisalign mandibular advancement with occlusal blocks continued to strengthen doctor confidence in the company’s offerings for younger patients.

During the question-and-answer session, Hogan described North American conditions as stable but uneven by region. He said growth in the DSO channel has helped offset weaker retail demand, while the company is seeking to improve North American retail performance through financing, clinical support, education and workflow initiatives.

Management said it is not assuming an improvement in the broader macroeconomic environment in its outlook. Instead, it pointed to patient financing, doctor subscription programs, lower-cost offerings and product innovation as drivers of future case volumes.

Scanner strategy weighs on reported systems revenue Systems and services revenue declined 10.8% year over year to $185.3 million. The segment includes iTero imaging systems, exocad CAD/CAM software and Align X-Ray Insight software.

Chief Financial Officer John Morici said the decline reflected lower scanner average selling prices, lower scanner wand sales and a strategic shift toward lower-cost scanner configurations, certified pre-owned units, leases and rentals. These options produce less upfront revenue than traditional scanner purchases but are intended to broaden access to the company’s digital workflow platform.

Despite the revenue decline, placements to new doctors reached a record and increased at a double-digit rate year over year. Align’s active scanner install base grew about 11%, while more than 12.4 million restorative, wellness and orthodontic scans were completed during the quarter, up 16%.

Hogan said the company views the lower upfront economics as a deliberate trade-off. Align expects a larger installed base to support recurring revenue and increase opportunities for Invisalign and restorative treatment adoption over time.

Exocad revenue grew at a double-digit rate during the quarter. The company also introduced exocad ART, or Advanced Restorative Treatment, which combines tooth alignment and restorative treatment planning within exocad software.

Margins, cash flow and shareholder returns Align’s GAAP operating income was $154 million, representing an operating margin of 14.6%, down about 1.5 percentage points from the prior year. GAAP diluted earnings per share were $1.51, down $0.20 year over year.

On a non-GAAP basis, operating margin rose 1.6 percentage points to 22.9%, and diluted earnings per share increased 6% to $2.64. The company said its non-GAAP results exclude items including stock-based compensation, certain legal settlements and contingencies, restructuring charges, and amortization of acquired intangible assets.

Overall gross margin was 71.7%, up 1.8 percentage points year over year, driven by operational efficiencies, a tariff refund and higher clear aligner average selling prices. Morici said lower refinement rates, improved treatment predictability and manufacturing throughput have supported margin expansion.

Cash and cash equivalents totaled $1.10 billion at June 30. The company generated $192.8 million in operating cash flow and $157.1 million in free cash flow during the quarter. Align repurchased about 393,400 shares for $67 million during the period.

The company now plans to repurchase approximately $400 million to $500 million of stock during 2026, including purchases under its previously announced $200 million open-market plan.

VAT charge, strategic review and outlook Align recorded an estimated $37.5 million liability, including interest, following a U.K. Upper Tribunal ruling that clear aligners do not qualify as VAT-exempt dental prostheses. The company said it will begin including 20% U.K. VAT on applicable Invisalign aligners and Vivera retainers on invoices beginning Sept. 7, while holding its list prices unchanged. Align intends to appeal the ruling.

The company also announced initiatives following discussions with Elliott Management, including plans to add three independent directors and conduct a comprehensive strategic and operating-model review with a global consulting firm. Hogan said the review will examine commercial execution, organizational effectiveness, scalability and resource optimization.

For the third quarter, Align forecast revenue of $1 billion to $1.02 billion. It expects clear aligner volumes to rise by the mid-single digits year over year, while clear aligner average selling prices are expected to decline sequentially due to geographic mix and foreign exchange effects.

Align expects third-quarter non-GAAP operating margin of approximately 24%, while GAAP operating margin is projected at 13.5% to 15%, reflecting anticipated restructuring, accelerated depreciation and other one-time charges.

For full-year 2026, the company maintained its forecast for revenue growth of 3% to 4%. It now expects clear aligner volume growth of approximately 6%, clear aligner average selling prices to be flat to slightly down, and systems and services revenue to decline 6% to 8%.

Morici said Align is not issuing formal 2027 guidance but is targeting at least 100 basis points of year-over-year improvement in both GAAP and non-GAAP operating margin next year, following its expected approximately 100-basis-point non-GAAP margin improvement in 2026.

About Align Technology (NASDAQ:ALGN)Align Technology, Inc NASDAQ: ALGN pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company's signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Align Technology Right Now?Before you consider Align Technology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Align Technology wasn't on the list.

While Align Technology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

LAS VEGAS & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from its 2026 Invisalign® Ortho Summit, held July 23–26, 2026 in Las Vegas. The Summit brought together more than 500 orthodontists and practice team members for an.

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the second quarter ("Q2'26"). Q2'26 total revenues were $1,056.2 million, up 1.5% sequentially and up 4.3% year-over-year. Q2'26 total revenues were unfavorably imp.

CompaniesJuly 29 (Reuters) - Align Technology (ALGN.O), opens new tab said on Wednesday it will add three new ​independent directors to its board and launch ‌a review of its operations, following talks with activist investor Elliott Investment Management.

Shares of the company ​were down 4.5% in extended trading.

Learn about the latest breakthroughs in AI and tech with the Reuters Artificial Intelligencer newsletter. Sign up here.

Align ​has hired a leading global consulting ⁠firm to conduct a comprehensive review of ​its operations and business model. The company ​said the review will focus on improving revenue growth and boosting profit margins.

The changes follow discussions ​with Elliott, one of Align's largest shareholders.

Marc ​Steinberg, a partner at Elliott, in a statement called ‌Align ⁠a market leader with significant growth potential. "We believe the board enhancements and other actions announced today are important steps toward ​delivering on ​this opportunity," ⁠he said.

The medical device company, best known for making Invisalign ​clear teeth aligners, said it raised ​its ⁠share buyback target for the year to between $400 million and $500 million, up from the ⁠earlier ​target of $200 million, citing ​confidence in its long-term value.

Reporting by Padmanabhan Ananthan in Bengaluru; ​Editing by Shailesh Kuber and Sahal Muhammed

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Posted by Defense World Staff on Jul 26th, 2026

Shares of Align Technology, Inc. (NASDAQ:ALGN – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $206.3571.

ALGN has been the topic of several research analyst reports. Leerink Partners raised their price target on Align Technology from $225.00 to $230.00 in a research report on Thursday, April 30th. Zacks Research cut Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 16th. Evercore increased their target price on Align Technology from $200.00 to $220.00 in a research note on Thursday, April 30th. Wall Street Zen raised Align Technology from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 4th. Finally, Citigroup began coverage on Align Technology in a research report on Wednesday, April 15th. They issued a “buy” rating and a $240.00 price target on the stock.

View Our Latest Stock Analysis on ALGN

Hedge Funds Weigh In On Align Technology A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bessemer Group Inc. boosted its holdings in Align Technology by 37.2% in the 1st quarter. Bessemer Group Inc. now owns 247 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 67 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. grew its position in Align Technology by 3.7% in the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 1,896 shares of the medical equipment provider’s stock worth $296,000 after purchasing an additional 68 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Align Technology by 77.5% during the 1st quarter. Blue Trust Inc. now owns 158 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 69 shares during the period. Comerica Bank increased its holdings in shares of Align Technology by 0.6% during the 4th quarter. Comerica Bank now owns 13,656 shares of the medical equipment provider’s stock worth $2,132,000 after purchasing an additional 76 shares during the period. Finally, First Bank & Trust raised its position in shares of Align Technology by 5.0% during the second quarter. First Bank & Trust now owns 1,599 shares of the medical equipment provider’s stock valued at $270,000 after buying an additional 76 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

Align Technology Trading Down 0.7% NASDAQ:ALGN opened at $167.01 on Thursday. Align Technology has a 1 year low of $122.00 and a 1 year high of $208.30. The firm’s fifty day simple moving average is $173.31 and its 200 day simple moving average is $175.01. The firm has a market capitalization of $11.96 billion, a PE ratio of 28.02, a PEG ratio of 1.71 and a beta of 1.67.

Align Technology (NASDAQ:ALGN – Get Free Report) last announced its earnings results on Wednesday, April 29th. The medical equipment provider reported $2.58 EPS for the quarter, topping the consensus estimate of $2.26 by $0.32. Align Technology had a net margin of 10.50% and a return on equity of 15.82%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the firm posted $2.13 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, analysts anticipate that Align Technology will post 9.48 EPS for the current fiscal year.

Align Technology announced that its board has authorized a stock repurchase plan on Wednesday, April 29th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 1.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

About Align Technology (Get Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Featured Stories Five stocks we like better than Align Technology Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBrokerages Set Graphic Packaging Holding Company (NYSE:GPK) Price Target at $11.03

NEXT HEADLINE »Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $24.25 Consensus Target Price from Analysts

TEMPE, Ariz & SAN JOSE, Calif.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced new innovations across its integrated Align™ Digital Platform*, designed to help doctors visualize, plan, and treat with greater confidence and predictability. Throug.

Key Takeaways ALGN is set to report Q2 2026 results on July 29, with revenues expected to grow 3.9% year over year. ALGN's Clear Aligner segment is expected to benefit from higher volumes across regions and patient groups.Align Technology's digital tools, scanner adoption and ART pilot may support second-quarter revenue growth. Align Technology, Inc. (ALGN - Free Report) is set to release second-quarter 2026 results on July 29, after the closing bell.

In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.58, which surpassed the Zacks Consensus Estimate by 14.16%. Align Technology beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 7.80%.

ALGN’s Q2 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $1.05 billion, which suggests 3.9% growth from the year-ago reported figure.

The Zacks Consensus Estimate for earnings is pinned at $2.56 per share, which implies a 2.8% rise from the year-ago recorded actuals.

Estimate Revision Trend Ahead of ALGN’s Q2 EarningsEstimates for second-quarter earnings have remained unchanged at $2.56 per share in the past 30 days.

Here’s a brief overview of the company’s performance leading up to this announcement.

Factors Shaping ALGN’s Q2 PerformanceClear Aligner

The segment is likely to have benefited from higher Clear Aligner volumes, with particular strength across the EMEA, APAC and Latin America, with continued stability in North America. Both orthodontists and GP dentist channels may have seen volume growth, driven by growth across adults, teens and growing kids. From a product standpoint, it is likely to have seen strong contributions from Invisalign First and the Invisalign Palatal Expander with Mandibular Advancement with Occlusal Blocks. 

Dental and orthodontic service organizations (DSOs) must have remained a key, scalable growth channel in the to-be-reported quarter, with continued strong progress across all major regions. Meanwhile, the doctor subscription program (DSP), which includes retention, touch-up and relapse cases, is expected to have maintained strong momentum during the quarter. 

The Zacks Consensus Estimate for Clear Aligner revenues indicates 6.3% year-over-year growth.

Align Technology, Inc. Price and EPS SurpriseImaging Systems & CAD/CAM Services (Systems and Services)

Within this segment, revenues are likely to have benefited from higher volumes across all regions and continued adoption of iTero Lumina scanner. In the first quarter, the total installed base of active scanners exceeded 125,000 globally. We expect this trend to have continued in the to-be-reported quarter as well. 

exocad achieved strong revenue growth, reinforcing the company’s strategy to integrate orthodontics and restorative dentistry within a customer and patient-centric digital platform. We expect this trend to have persisted in the second quarter as well. Following the successful launch of Invisalign Advanced Restorative Treatment (ART) pilot in the EMEA, Align recently began an Invisalign ART pilot in the United States with labs and doctors beginning training in several markets. We expect the development to have contributed to the company’s top-line growth. 

The company’s growing suite of digital diagnostic tools, including Align Oral Health Suite and Align X-ray Insights, helps doctors identify conditions earlier and deliver clearer, more informed treatment recommendations. We expect all these tools to have positively impacted Align Technology’s revenues in the second quarter.

The Zacks Consensus Estimate for the segment’s revenues implies a decrease of 5.5% on a year-over-year basis.

What Our Quantitative Model Predicts for ALGNPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below:

Earnings ESP: Align Technology has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.

Stocks Worth a LookHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:

Hinge Health Inc. (HNGE - Free Report) has an Earnings ESP of +4.24% and a Zacks Rank #1. The company is expected to release second-quarter 2026 results soon.

In the trailing four quarters, HINGE delivered an average surprise of 179.54%. The Zacks Consensus Estimate for second-quarter EPS implies a decrease of 11.9% from the year-ago quarter’s figure.

Neurocrine Biosciences (NBIX - Free Report) has an Earnings ESP of +40.60% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon.

NBIX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.08%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for an increase of 112.3% from the year-ago quarter’s figure.

West Pharmaceutical Services (WST - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2026 results on July 23. 

WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.37%. The Zacks Consensus Estimate for WST’s second-quarter EPS implies a rise of 13% from the year-ago reported figure.

Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Align Technology (ALGN - Free Report) and Straumann Holding AG (SAUHY - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Currently, both Align Technology and Straumann Holding AG are holding a Zacks Rank of #2 (Buy). Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. But this is only part of the picture for value investors.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

ALGN currently has a forward P/E ratio of 15.80, while SAUHY has a forward P/E of 32.31. We also note that ALGN has a PEG ratio of 1.54. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SAUHY currently has a PEG ratio of 2.41.

Another notable valuation metric for ALGN is its P/B ratio of 3.1. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, SAUHY has a P/B of 7.95.

These metrics, and several others, help ALGN earn a Value grade of B, while SAUHY has been given a Value grade of D.

Both ALGN and SAUHY are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that ALGN is the superior value option right now.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Considering buying ALGN stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

-

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today responded to the European Commission’s June 30 press release announcing an investigation involving the Company based on a complaint made by an Align competitor.

Align Technology is committed to conducting business with integrity and in full compliance with global competition laws. We believe fair, lawful competition drives innovation, expands choice, and delivers better outcomes for doctors and patients. Our success in the teeth-straightening market is built on the strength of our products and services — quality, innovation, and customer experience — not on unfair practices, and we strongly dispute any suggestion to the contrary.

Align’s iTero intraoral scanning platform is designed to support an open and diverse digital dental ecosystem, and supports a wide range of clinical workflows, including implants, restorative dentistry, digital orthodontics, and clear aligner treatment. iTero generated scans can be freely exported to order aligners other than Invisalign aligners. Align maintains a scan acceptance policy designed to ensure clinical quality, patient safety, and system reliability, including validation requirements for digital file submissions and the operational resources needed to support consistent processing across workflows.

The iTero intraoral scanning platform is used globally by dental professionals across diverse treatment modalities, with millions of scans performed annually, reflecting its role in enabling a broad and competitive marketplace for digital dentistry solutions. Since 2018, the iTero scanner has been used by healthcare professionals to perform over 24 million restorative, wellness, and orthodontic scans.

The Commission’s step is purely procedural and allows it to gather information. It does not reflect a conclusion on the merits of the case, nor does it constitute an accusation or a finding of wrongdoing. The opening of an investigation does not prejudge its outcome.

Align is confident that any review of Align’s scanner and scan acceptance policies will reflect the robust and dynamic nature of the teeth-straightening market and believes its practices comply with applicable competition laws. We will cooperate fully and engage constructively with the Commission through the appropriate channels.

For nearly 30 years, Align Technology has helped transform a market long dominated by wires and brackets, offering meaningful choices to customers across Europe and around the world. By introducing innovative digital dentistry solutions that expand treatment possibilities for doctors and their patients, Align has helped doctors transform smiles and change lives for millions of patients, a testament to the value of innovation and better patient experience. What began as an innovation has grown into a widely accepted treatment category, one that now extends beyond Invisalign aligners and iTero scanners across a diverse and competitive ecosystem.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

More News From Align Technology, Inc.

Back to Newsroom

Investors interested in Medical - Dental Supplies stocks are likely familiar with Align Technology (ALGN) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that C. Raymond Larkin, Jr. will retire as Chairman of the Board effective July 1, 2026, following more than 20 years of distinguished service on Align’s Board of Directors. Mr. Larkin will continue to serve on the Board and as a member of the Nominating and Governance Committee through December 31, 2026, to support a smooth transition.

Kevin Conroy will succeed Mr. Larkin as Chairman of the Board, effective July 1, 2026. Mr. Conroy has served as an independent director since his appointment to the Board in December 2023 and Chair of the Compensation and Human Capital Committee of the Board since January 2026.

“On behalf of the entire Board and management team, I would like to express our deep gratitude to Ray for his extraordinary leadership, partnership, and enduring contributions to Align over more than two decades,” said Joe Hogan, Align Technology president and chief executive officer. “Ray has been instrumental in guiding Align through multiple phases of growth, innovation, and scale. His strategic insight, deep experience in healthcare, and unwavering commitment to strong governance have helped shape Align into the global leader it is today.”

Mr. Hogan continued, “We are pleased to welcome Kevin as our next Chairman. Kevin brings extensive experience as a board leader and recently as CEO of Exact Sciences prior to its acquisition by Abbott Laboratories in March 2026. He has demonstrated a strong track record of creating stockholder value, and deep expertise in healthcare, technology, and strategy. His leadership will help guide Align through our next chapter of growth and innovation.”

Mr. Larkin added, “It has been an honor to serve as Chairman of Align. I am incredibly proud of all that Align has achieved and confident in its continued leadership in digital dentistry. I look forward to supporting Kevin and the Board during this transition and seeing Align continue to transform smiles and improve patient outcomes around the world well into the future.”

Mr. Conroy said, “I am honored to be appointed Chairman of Align’s Board. Align has a strong foundation, an exceptional leadership team, and significant opportunities ahead. I look forward to working closely with Joe, the Board, and management to continue driving innovation, expanding access to digital orthodontics, and creating long-term value for our stockholders.”

ABOUT C. RAYMOND LARKIN, JR.

Mr. Larkin has served as a member of Align’s Board since 2004. He has decades of leadership experience in the medical device and healthcare industries, including serving as President and Chief Executive Officer of Nellcor Puritan Bennett, where he led the company’s growth to nearly $1 billion in revenue and helped establish pulse oximetry as a global standard of care. Throughout his tenure at Align, Mr. Larkin has provided strategic guidance across periods of significant growth and innovation, drawing on his extensive public and private company board experience and deep expertise in healthcare.

ABOUT KEVIN CONROY

Mr. Conroy has served as an independent director of Align since December 2023 and Chair of the Compensation and Human Capital Committee of the Board since January 2026. He brings extensive experience as a business, legal, and strategic leader, including serving as Chairman and Chief Executive Officer of Exact Sciences Corp. until its acquisition by Abbott Laboratories in March 2026, where he led the commercialization of Cologuard and grew the company to $3.25 billion in annual revenue while serving millions of patients. Prior to Exact Sciences, Mr. Conroy served as President and CEO of Third Wave Technologies and held leadership roles at GE Healthcare. He currently serves on the board of Abbott Laboratories and brings deep expertise in healthcare innovation, strategy, and governance.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

More News From Align Technology, Inc.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Align Technology (ALGN - Free Report) Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

ALGN is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 13.85; value investors should take notice.

Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.12 to $11.35 per share. ALGN also boasts an average earnings surprise of +7.8%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, ALGN should be on investors' short list.

-

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financial conferences. As noted below, the presentations will be webcast live via the Investor Relations section of Align Technology's website at http://investor.aligntech.com. An archived replay will remain on the website for approximately one month.

Conference:

Stifel 2026 Jaws & Paws Conference

Date:

Thursday, May 28, 2026

Presentation:

8:00 – 8:30 a.m. ET

Location:

New York, NY

Speakers:

John Morici, EVP Global Finance and CFO

Shirley Stacy, VP Finance, Global Communications and IRO

Conference:

William Blair 46th Annual Growth Stock Conference

Date:

Wednesday, June 3, 2026

Presentation:

9:20 – 9:50 a.m. CT

Location:

Chicago, IL

Speakers:

Joseph Hogan, CEO

John Morici, EVP Global Finance and CFO

Shirley Stacy, VP Finance, Global Communications and IRO

Conference:

2026 Jefferies Global Healthcare Conference

Date:

Thursday, June 4, 2026

Presentation:

8:10 – 8:40 a.m. ET

Location:

New York, NY

Speakers:

John Morici, EVP Global Finance and CFO

Shirley Stacy, VP Finance, Global Communications and IRO

Conference:

Goldman Sachs 47th Annual Global Healthcare Conference

Date:

Monday, June 8, 2026

Presentation:

8:40 – 9:15 a.m. ET

Location:

Miami, FL

Speakers:

John Morici, EVP Global Finance and CFO

Shirley Stacy, VP Finance, Global Communications and IRO

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

More News From Align Technology, Inc.

Back to Newsroom